LeonaBio Fortifies Board for Pivotal Drug Development Push

BOTHELL, WA – May 07, 2026 – Clinical-stage biopharmaceutical company LeonaBio, Inc. (NASDAQ: LONA) has significantly reshaped its leadership team, signaling a strategic acceleration as it approaches critical milestones for its lead drug candidates in oncology and neurology. The company announced the appointment of three seasoned industry veterans—Fred Callori, J.D., Natalie Holles, and Peter B. Silverman, J.D.—to its Board of Directors, effective May 5. The move comes as long-serving director John Fluke, Jr. retires after a decade of service.

The appointments are not a routine shuffle but a calculated reinforcement of the company’s capabilities in drug development, corporate strategy, and capital markets. This strategic enhancement arrives at a crucial moment for LeonaBio, which is advancing a late-stage trial for metastatic breast cancer and preparing to launch a Phase 2 study for amyotrophic lateral sclerosis (ALS).

“We are delighted to welcome Fred, Natalie, and Peter to LeonaBio’s Board of Directors,” said Mark Litton, Ph.D., President and Chief Executive Officer of LeonaBio. “Collectively, they bring significant drug development experience across different oncology and neurology settings, proven leadership in corporate strategy and operational execution, and capital markets expertise. Their backgrounds and capabilities are directly aligned with our clinical focus and will be instrumental as we advance our pipeline and position the company for its next phase of growth.”

Dr. Litton also expressed gratitude for the outgoing director, stating, “On behalf of the Board of Directors and management team, I would also like to express our sincere appreciation to John Fluke for his thoughtful counsel and dedicated service over the past decade.”

The Architects of a New Strategy

The new board members bring a formidable and diverse set of skills tailored to LeonaBio's immediate and long-term needs. Their collective track record suggests a focus on execution, financial fortification, and strategic deal-making.

Fred Callori brings deep financial acumen from his role as a Partner and Managing Director at Perceptive Advisors, an investment firm renowned for its sharp focus on the biotechnology sector. His experience, which also includes leadership at life sciences accelerator Xontogeny, is directly relevant to a company like LeonaBio, which must navigate the volatile biotech funding landscape to support its costly late-stage clinical trials. His appointment signals a proactive approach to securing the capital necessary to see its programs through to completion.

Natalie Holles adds extensive operational and executive leadership experience, having served as CEO at Aura Biosciences and Third Harmonic Bio, and President and CEO at Audentes Therapeutics. Her career is marked by guiding clinical-stage companies through the complex phases of drug development and corporate growth. This hands-on experience in trial execution and strategic planning will be invaluable as LeonaBio manages its pivotal Phase 3 study and prepares for potential regulatory submissions and commercialization.

Peter B. Silverman provides a critical layer of legal and corporate development expertise. His tenure as Chief Operating Officer at Merus N.V. until its acquisition, combined with his background as a partner at the international law firm Kirkland & Ellis LLP, equips him to guide LeonaBio through complex intellectual property, regulatory, and transactional landscapes. In a biotech M&A market that is showing a strong rebound in 2026, his expertise could be pivotal in exploring strategic partnerships, licensing deals, or positioning the company for a future acquisition.

High-Stakes Pipeline Nears Key Inflection Points

The board's reinforcement comes as LeonaBio’s pipeline advances toward significant data readouts. The company's future is largely tied to two promising, high-risk, high-reward assets.

Its lead candidate, lasofoxifene, is being evaluated for treatment-resistant metastatic breast cancer. It is currently in a registrational Phase 3 trial known as ELAINE-3. The study is testing lasofoxifene in combination with a CDK4/6 inhibitor against the current standard of care in patients with ER+/HER2- breast cancer who have an ESR1 mutation—a common driver of treatment resistance. Following promising Phase 2 data, LeonaBio recently expanded the trial's size to 600 participants to strengthen its statistical power. Enrollment is expected to complete in the fourth quarter of 2026, with crucial topline data anticipated in the second half of 2027.

The second lead asset, ATH-1105, targets amyotrophic lateral sclerosis (ALS), a devastating neurodegenerative disease with a profound unmet medical need. After demonstrating a favorable safety profile and central nervous system penetration in a Phase 1 study, LeonaBio is on track to initiate a Phase 2 proof-of-concept study in ALS patients in the second half of this year. ATH-1105 is a novel small molecule designed to modulate the neurotrophic HGF system, representing a new approach in a field desperate for effective therapies.

Navigating a Dynamic and Competitive Landscape

LeonaBio operates in two of the most competitive and challenging areas of drug development. In the ER+/HER2- breast cancer space, the market is crowded with established therapies and a wave of new oral Selective Estrogen Receptor Degraders (SERDs) and other targeted agents. The ELAINE-3 trial's head-to-head design is an ambitious gamble, but a positive outcome could position lasofoxifene as a new standard of care for a well-defined patient population.

The ALS landscape is equally daunting, littered with clinical trial failures. However, recent approvals like Tofersen for a specific genetic subset of patients have renewed hope and investment in the field. With over 90 novel treatments in development, ATH-1105's unique mechanism could allow it to carve out a significant position if its upcoming Phase 2 trial demonstrates a meaningful clinical benefit.

Fortifying the Balance Sheet for the Road Ahead

Advancing a late-stage pipeline requires significant capital. LeonaBio reported cash, cash equivalents, and investments of $67.7 million as of March 31, 2026, which management believes is sufficient to fund operations for at least the next 12 months. This runway is supported by a $90 million private placement completed in December 2025. However, R&D expenses are rising, hitting $11.3 million in the first quarter of 2026 as clinical activities ramped up.

With the ELAINE-3 trial running through 2027 and a new Phase 2 study starting, the company will inevitably need more funding. The appointment of an investor of Fred Callori's caliber is a clear indicator that financial strategy is a top priority. Despite the company's current net loss, a common feature of clinical-stage biotechs, market analysts have shown optimism. Mizuho recently raised its price target on LONA shares to $16, a significant premium over its current trading price, suggesting confidence in the pipeline's long-term potential. The strategic board appointments are designed to ensure the company has the leadership, expertise, and financial backing to turn that potential into reality for patients and investors.